No doubt abdm is preparing a response to your enquiry as I type this post, so in the meantime, here is my understanding to date from publicly released announcements that relate to P&G and the hypothesising of Bakers and many on Hotcopper in relation to Olay as the first Product License.
28/09/2010 Strategic Alliance with Global FMCG Company:
'If agreed developmental objectives and criteria are met, and the FMCG company commercialises products within the field, OBJ will grant a license for each product within the field and receive royalties for a period of 5 years or life of patent, whichever is longer'.
25/10/2010 Shareholder Update and Quarterly Repost:
'The Strategic Alliance with a major FMCG company announced in September 2010 is progressing on schedule with the arrival of a number of drug candidates that will form part of the Technical Evaluation phase of the Strategic Alliance. The drugs and active ingredients received are from existing commercial products of the FMCG company with global sales.'
25/10/2011 Global FMCG Company to Secure Access Rights for Beauty Care:
'The results met the FMCG company's success criteria and the parties have now moved to negotiations of a JDA in the Beauty Care field.'
'Beauty care is a multti-billion dollar consumer and professional products category that includes skin care, colour cosmetics, fragrances, deodorants and antiperspirants, personal healthcare, hair care, shaving and grooming products.'
'P&G is the world's largest consumer products company with a brand portfolio of over 300 household names - from Gillette to Duracell, Olay to cover Girl. P&G provides global market access across 180 countries and serves some 4.4 billion consumers daily. P&G's annual turnover is about $US83 billion/annum.'
15/08/2012 Shareholder Update:
'This first program progresses to the next development stage in the USA while a second program involving a new P&G nominated molecule enters development by our R&D team.'
'Human clinical trials represent the culmination of the research and development phases under the JDA for these first two molecules.'
'The devices to be used by consumers in the clinical trials were designed and developed by OBJ's Perth based scientific team, led by Dr Matt McIldowie. The units were manufactured in Singapore to the necessary standard and quality for the trials.'
'Following completion of a clinical study into the effect of OBJ's magnetic micro-array technology, P&G and OBJ are in negotiation regarding the possible product development if the first application for OBJ's technology within P&G's product range.'
'The 80 person study sought to evaluate the efficacy of OBJ's non-powered Wand technology on a range of industry standard cosmetic Indices using high resolution imagery, expert dermatology evaluations and consumer perception data. Negotiations are underway for the Company's first Product Development and an expansion of the work programs into a number of new categories.'
28/04/2014 P&G Signs Multi Product PDA inc. First Product License:
'P&G and OBJ have been working together under a JDA since 2011 with the shared goal of creating breakthrough innovation that provides meaningful benefits for consumers. the signing of the JDA, agreed Licensing terms and initial product development plans is the culmination of a 3 year development and testing program conducted under the JDA, involving a number of P&G's International brand teams.'
'Under the PDA, OBJ grants to P&G a world-wide exclusive right to commercialise OBJ's non-powered magnetic micro-array technology within specifically defined product categories.'
'Gillette, Duracell, Olay and Covergirl are just a few of P&G's vast product range.'
So Twin here's what we do know. Neither OBJ or P&G have categorically confirmed what the first Product License will be. Many here on Hotcopper have been trying to make a calculated guess based on the information that has been released for well over 12 months now and I believe this is exactly what Bakers have done as well.
We know that P&G have secured Access Rights and exclusivity for the Beauty Care Sector. We also know that P&G have world-wide exclusive right to commercialise OBJ's non-powered magnetic micro-array technology within specifically defined product categories. The Human Clinical trial used the non-powered Wand technology on a range of industry standard cosmetic Indices using high resolution imagery, expert dermatology evaluations. We also know it is for a product with existing Global Sales and it's a device. And we also know that over numerous announcements we have been provided graphical pictures that represent facial creams and devices and the Olay brand is one of P&G's multi-billion dollar brands.
Putting all of this information together, it is not too much of a stretch to hypothesise that Olay is indeed a front-runner for the first Product License. I have also previously mentioned that SKII could also be a front-runner.
As mentioned numerous times on this forum in the past, while some wait for OBJ to be further de-risked by the company spelling out exactly the 'who's' and 'what's', others are already more than comfortable with their Investment decision to already be invested.
We will categorically know when P&G are ready to launch so that they are undoubtedly able to maintain their competitive edge that has kept them in the No 1 FMCG position Globally.
OBJ Price at posting:
7.6¢ Sentiment: LT Buy Disclosure: Held
(20min delay)